公开(公告)号：US20210179716A1

公开(公告)日：2021-06-17

申请号：US17120935

申请日：2020-12-14

Applicant: Pfizer Inc.

Inventor： Javier Fernando CHAPARRO RIGGERS ,  Shih-Hsun CHEN ,  Sheng DING ,  Pawel Kamil DOMINIK ,  Shahram SALEK-ARDAKANI ,  Jessica Lynn Stanfield ,  Thomas John VAN BLARCOM

IPC: C07K16/28 ,  A61P35/00

Abstract: Antibodies that specifically bind to CD47 and antibodies that specifically bind to PD-L1 are provided, as well as CD47/PD-L1 bispecific antibodies. Also provided are uses of these antibodies, and related compositions and methods.

公开(公告)号：US20240018252A1

公开(公告)日：2024-01-18

申请号：US18456399

申请日：2023-08-25

Applicant: PFIZER INC.

Inventor： Tracy Chia-Chien KUO ,  Javier Fernando CHAPARRO RIGGERS ,  Wei CHEN ,  Amy Shaw-Ru CHEN ,  Edward Derrick PASCUA ,  Thomas John VAN BLARCOM ,  Leila Marie BOUSTANY ,  Weihsien HO ,  Yik Andy YEUNG ,  Pavel STROP ,  Arvind RAJPAL

IPC: C07K16/28 ,  A61K31/454 ,  A61K39/395 ,  A61K38/07 ,  A61P35/00 ,  A61K31/704

CPC classification number: C07K16/2878 ,  C07K16/2809 ,  A61K31/454 ,  A61K39/3955 ,  A61K38/07 ,  A61P35/00 ,  A61K31/704 ,  C07K2317/31 ,  A61K39/00

Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

公开(公告)号：US20230192839A1

公开(公告)日：2023-06-22

申请号：US16500970

申请日：2018-03-29

Applicant: PFIZER INC.

Inventor： Bijan Andre BOLDAJIPOUR ,  Javier Fernando CHAPARRO RIGGERS ,  Xiaodi DENG ,  Kevin Charles LINDQUIST ,  Spencer PARK ,  Edward Derrick PASCUA ,  Thomas John VAN BLARCOM

IPC: C07K16/28 ,  C07K16/00 ,  C12N15/63

CPC classification number: C07K16/28 ,  C07K16/005 ,  C12N15/63 ,  C07K2317/92 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/03

Abstract: Provided herein are antibodies with conditional affinity for an antigen. The affinity of an antibody with conditional affinity for an antigen may be altered by a small molecule agent. Antibodies with conditional affinity may be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

公开(公告)号：US20220227832A1

公开(公告)日：2022-07-21

申请号：US17557654

申请日：2021-12-21

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Shanshan LANG ,  Thomas John VAN BLARCOM ,  Michael Thomas BETHUNE ,  Siler PANOWSKI ,  Nguyen TAN ,  Yi ZHANG ,  Barbra Johnson SASU ,  Zhe LI

IPC: C07K14/725 ,  C07K14/705 ,  C12N15/79 ,  C07K19/00

Abstract: A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. Nucleic acids including vectors and expression vectors that encode the protease-activating CD45-gate CAR and cells including immune cells such as T cells that comprise and express the nucleic acids. Methods of treatment of various conditions including various forms of cancer comprising administering the cells including CAR T cell therapy. In some embodiments, the CD45 gate at least partially inhibits activation of the protease-activating CD45-gate CAR when the protease-activating CD45-gate CAR binds antigen. The inhibition is at least partially diminished, relieved and/or eliminated when the protease-activating CD45-gate CAR is exposed to a protease that can cleave the linker.

公开(公告)号：US20180298108A1

公开(公告)日：2018-10-18

申请号：US16017974

申请日：2018-06-25

Applicant: PFIZER INC.

Inventor： Tracy Chia-Chien KUO ,  Javier Fernando CHAPARRO RIGGERS ,  Wei CHEN ,  Amy Shaw-Ru CHEN ,  Edward Derrick PASCUA ,  Thomas John VAN BLARCOM ,  Leila Marie BOUSTANY ,  Weihsien HO ,  Yik Andy YEUNG ,  Pavel STROP ,  Arvind RAJPAL

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/704 ,  A61K31/454 ,  A61K47/68

Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.